BREAKING NEWS: FDA seeks probe into communications between its staff and Biogen after controversial approval of Alzheimer’s drug
FDA commissioner Janet Woodcock has asked for a probe into her staff’s communications with Biogen
Biogen’s Aduhelm received FDA approval for Alzheimer’s disease in early June
despite limited data that it worked in clinical trials
In the month since, three members of an FDA advisory committee have resigned in protest of the drug’s approval
A House investigation has been launched into the large, $56,000, price tag of the drug
COVID-19 Vaccines Could Be Spurring Variants, Say Israeli and European Experts